FDA's NDA And BLA Approvals: Zejula, Ocrevus, Dupixent
Executive Summary
Original new drugs and biologics recently approved by US FDA.
You may also be interested in...
Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval
Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.
Broad Label Gives Tesaro's Niraparib A Head Start In Ovarian Cancer
Tesaro takes opportunity of broad approval for Zejula (niraparib) in recurrent ovarian cancer to highlight franchise expansion opportunities in other tumor types, including PD-1 inhibitor combination studies.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.